| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| b' C\\xc3\\xa9sar Quiroz, Seema Gulyani, Wan Ruiqian, Jordi Bonaventura, Roy Cutler, Virginia Pearson, Richard P Allen, Christopher J Earley, Mark P Mattson, Sergi Ferr\\xc3\\xa. Adenosine receptors as markers of brain iron deficiency: Implications for Restless Legs Syndrome. Neuropharmacology. vol 111. 2017-07-11. PMID:27600688.' |
deficits of sensorimotor integration with periodic limb movements during sleep (plms) and hyperarousal and sleep disturbances in restless legs syndrome (rls) constitute two pathophysiologically distinct but interrelated clinical phenomena, which seem to depend mostly on alterations in dopaminergic and glutamatergic neurotransmission, respectively. |
2017-07-11 |
2023-08-13 |
Not clear |
| Beatrice Heim, Atbin Djamshidian, Anna Heidbreder, Ambra Stefani, Laura Zamarian, Marie-Theres Pertl, Elisabeth Brandauer, Margarete Delazer, Klaus Seppi, Werner Poewe, Birgit Hög. Augmentation and impulsive behaviors in restless legs syndrome: Coexistence or association? Neurology. vol 87. issue 1. 2017-05-05. PMID:27261093. |
to assess the frequency of impulse control disorders (icds) in patients with restless legs syndrome (rls) with and without augmentation under dopaminergic therapy in a case-control study. |
2017-05-05 |
2023-08-13 |
Not clear |
| Th Zambelis, B R Wolgamuth, S N Papoutsi, N T Economo. Restless legs syndrome mimicking S1 radiculopathy. Psychiatrike = Psychiatriki. vol 27. issue 3. 2017-04-03. PMID:27837576. |
with the use of restless legs syndrome appropriate treatment (pramipexole 0.18 mg taken at bedtime, a dopaminergic agent and level a recommended drug for restless legs syndrome) an excellent response and immediate elimination of symptoms was achieved. |
2017-04-03 |
2023-08-13 |
Not clear |
| Elena Marchesi, Anna Negrotti, Monica Angelini, Matteo Goldoni, Giorgia Abrignani, Stefano Calzett. A prospective study of the cumulative incidence and course of restless legs syndrome in de novo patients with Parkinson's disease during chronic dopaminergic therapy. Journal of neurology. vol 263. issue 3. 2016-12-13. PMID:26566909. |
a prospective study of the cumulative incidence and course of restless legs syndrome in de novo patients with parkinson's disease during chronic dopaminergic therapy. |
2016-12-13 |
2023-08-13 |
Not clear |
| Elena Marchesi, Anna Negrotti, Monica Angelini, Matteo Goldoni, Giorgia Abrignani, Stefano Calzett. A prospective study of the cumulative incidence and course of restless legs syndrome in de novo patients with Parkinson's disease during chronic dopaminergic therapy. Journal of neurology. vol 263. issue 3. 2016-12-13. PMID:26566909. |
the authors report the cumulative incidence of restless legs syndrome (rls) over a 3 years follow-up period in 92 de novo parkinson's disease patients under chronic dopaminergic therapy and the clinical course of the sensory-motor disorder over 12 months as from its onset. |
2016-12-13 |
2023-08-13 |
Not clear |
| Elena Marchesi, Anna Negrotti, Monica Angelini, Matteo Goldoni, Giorgia Abrignani, Stefano Calzett. Erratum to: A prospective study of the cumulative incidence and course of restless legs syndrome in de novo patients with Parkinson's disease during chronic dopaminergic therapy. Journal of neurology. vol 263. issue 3. 2016-07-11. PMID:26895039. |
erratum to: a prospective study of the cumulative incidence and course of restless legs syndrome in de novo patients with parkinson's disease during chronic dopaminergic therapy. |
2016-07-11 |
2023-08-13 |
Not clear |
| James E Frampto. Oxycodone/Naloxone PR: A Review in Severe Refractory Restless Legs Syndrome. CNS drugs. vol 29. issue 6. 2016-06-15. PMID:26135898. |
an oral, fixed-dose combination of prolonged-release (pr) oxycodone with pr naloxone (targin(®), targiniq(®), targinact(®); hereafter referred to as oxycodone/naloxone pr) is approved in europe for the second-line symptomatic treatment of patients with severe to very severe idiopathic restless legs syndrome (rls), after failure of dopaminergic therapy. |
2016-06-15 |
2023-08-13 |
Not clear |
| Camilla Rocchi, Maria Albanese, Fabio Placidi, Andrea Romigi, Benedetta Lauretti, Girolama A Marfia, Claudio Liguori, Maria G Marciani, Nicola B Mercuri, Francesca Izz. Chronic dopaminergic treatment in restless legs syndrome: does it affect the autonomic nervous system? Sleep medicine. vol 16. issue 9. 2016-06-15. PMID:26298781. |
chronic dopaminergic treatment in restless legs syndrome: does it affect the autonomic nervous system? |
2016-06-15 |
2023-08-13 |
Not clear |
| S Kassel, J S Schwed, H Star. Dopamine D3 receptor agonists as pharmacological tools. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 25. issue 9. 2016-06-08. PMID:25498414. |
dysregulation of the dopaminergic innervation in the central nervous system plays a key role in different neurological disorders like parkinson´s disease, restless legs syndrome, schizophrenia etc. |
2016-06-08 |
2023-08-13 |
Not clear |
| Diego García-Borreguer. Dopaminergic Augmentation in Restless Legs Syndrome/Willis-Ekbom Disease: Identification and Management. Sleep medicine clinics. vol 10. issue 3. 2016-05-31. PMID:26329438. |
augmentation is the main clinical complication of long-term dopaminergic treatment of restless legs syndrome (rls)/willis-ekbom disease and also the main reason for treatment failure of this class of drugs. |
2016-05-31 |
2023-08-13 |
Not clear |
| Ana Marques, Maria Livia Fantini, Dominique Morand, Bruno Pereira, Philippe Derost, Miguel Ulla, Bérengère Debilly, Jean-Jacques Lemaire, Franck Duri. Emergence of restless legs syndrome after subthalamic stimulation in Parkinson's disease: a dopaminergic overstimulation? Sleep medicine. vol 16. issue 5. 2016-04-25. PMID:25881920. |
emergence of restless legs syndrome after subthalamic stimulation in parkinson's disease: a dopaminergic overstimulation? |
2016-04-25 |
2023-08-13 |
Not clear |
| Ji-Ye Jeon, Hye-Jin Moon, Mei Ling Song, Hochang B Lee, Yong Won Ch. Augmentation in restless legs syndrome patients in Korea. Sleep & breathing = Schlaf & Atmung. vol 19. issue 2. 2016-04-07. PMID:25082663. |
augmentation has been known as the major complication of long-term dopaminergic treatment of restless legs syndrome (rls). |
2016-04-07 |
2023-08-13 |
Not clear |
| Christopher J Earley, James Connor, Diego Garcia-Borreguero, Peter Jenner, John Winkelman, Phyllis C Zee, Richard Alle. Altered brain iron homeostasis and dopaminergic function in Restless Legs Syndrome (Willis-Ekbom Disease). Sleep medicine. vol 15. issue 11. 2015-07-27. PMID:25201131. |
altered brain iron homeostasis and dopaminergic function in restless legs syndrome (willis-ekbom disease). |
2015-07-27 |
2023-08-13 |
Not clear |
| Adam Rosenstein, Marcie Rabin, Roger Kurla. Augmentation in Restless Legs Syndrome: Treatment with Gradual Medication Modification. The open neurology journal. vol 9. 2015-06-24. PMID:26106453. |
dopaminergic drugs can cause augmentation during the treatment of restless legs syndrome (rls). |
2015-06-24 |
2023-08-13 |
Not clear |
| Thomas Mitterling, Birgit Frauscher, Tina Falkenstetter, Viola Gschliesser, Laura Ehrmann, David Gabelia, Elisabeth Brandauer, Werner Poewe, Birgit Hög. Is there a polysomnographic signature of augmentation in restless legs syndrome? Sleep medicine. vol 15. issue 10. 2015-06-22. PMID:25129261. |
augmentation of restless legs syndrome (rls) is a potentially severe side-effect of dopaminergic treatment. |
2015-06-22 |
2023-08-13 |
Not clear |
| Arturo Benitez, Heather Edens, Jesse Fishman, Kimberly Moran, Mahnaz Asgharneja. Rotigotine transdermal system: developing continuous dopaminergic delivery to treat Parkinson's disease and restless legs syndrome. Annals of the New York Academy of Sciences. vol 1329. 2015-01-26. PMID:25145951. |
rotigotine transdermal system: developing continuous dopaminergic delivery to treat parkinson's disease and restless legs syndrome. |
2015-01-26 |
2023-08-13 |
Not clear |
| Arturo Benitez, Heather Edens, Jesse Fishman, Kimberly Moran, Mahnaz Asgharneja. Rotigotine transdermal system: developing continuous dopaminergic delivery to treat Parkinson's disease and restless legs syndrome. Annals of the New York Academy of Sciences. vol 1329. 2015-01-26. PMID:25145951. |
although the etiology is unknown, restless legs syndrome (rls) is thought to involve dopaminergic dysregulation. |
2015-01-26 |
2023-08-13 |
Not clear |
| Sophie Bayard, Muriel Croisier Langenier, Yves Dauvillier. Decision-making, reward-seeking behaviors and dopamine agonist therapy in restless legs syndrome. Sleep. vol 36. issue 10. 2014-06-23. PMID:24082309. |
to assess whether the frequency of impulse control disorders (icds), addictive behaviors, impulsivity, and impairment of decision-making task performance under ambiguous and risky conditions were present in patients with restless legs syndrome (rls) and whether changes could be related to dopaminergic medications. |
2014-06-23 |
2023-08-12 |
Not clear |
| Hongkuan Yang, Mingchun Yang, Hongpeng Guan, Ziyi Liu, Shiguang Zhao, Shigeko Takeuchi, Daijiro Yanagisawa, Ikuo Tooyam. Mitochondrial ferritin in neurodegenerative diseases. Neuroscience research. vol 77. issue 1-2. 2014-06-19. PMID:23916831. |
ftmt expression was also detected in dopaminergic neurons in the substantia nigra and was increased in patients with restless legs syndrome, while ftmt had a protective effect against cell death in a neuroblastoma cell line model of parkinson's disease. |
2014-06-19 |
2023-08-12 |
human |
| Mahek Mirza, Win-Kuang Shen, Aamir Sofi, Canh Tran, Ahad Jahangir, Sulaiman Sultan, Uzma Khan, Maria Viqar, Chi Cho, Arshad Jahangi. Frequent periodic leg movement during sleep is an unrecognized risk factor for progression of atrial fibrillation. PloS one. vol 8. issue 10. 2014-06-05. PMID:24147132. |
in patients with frequent periodic leg movement during sleep, dopaminergic therapy for control of leg movements in patients with restless legs syndrome reduced risk of atrial fibrillation progression. |
2014-06-05 |
2023-08-12 |
Not clear |